Last reviewed · How we verify
Ticagrelor plus ASA
Ticagrelor plus ASA inhibits platelet activation and aggregation by blocking the P2Y12 receptor and irreversibly inhibiting COX-1.
Ticagrelor plus ASA inhibits platelet activation and aggregation by blocking the P2Y12 receptor and irreversibly inhibiting COX-1. Used for Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome or a history of myocardial infarction, Reduction of stroke risk in patients with a history of ischemic stroke or transient ischemic attack.
At a glance
| Generic name | Ticagrelor plus ASA |
|---|---|
| Also known as | Brilique plus aspirin |
| Sponsor | University of Athens |
| Drug class | antiplatelet |
| Target | P2Y12 receptor, COX-1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ticagrelor is a reversible P2Y12 receptor antagonist, while ASA (acetylsalicylic acid) irreversibly inhibits COX-1, leading to a decrease in thromboxane A2 production and subsequent platelet aggregation. This combination therapy is used to reduce the risk of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Approved indications
- Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome or a history of myocardial infarction
- Reduction of stroke risk in patients with a history of ischemic stroke or transient ischemic attack
Common side effects
- Bleeding
- Thrombocytopenia
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- The 10-Year Extended Follow-up of the DACAB Trial
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |